PSTX - Poseida Therapeutics GAAP EPS of -$0.25 revenue of $28.14M
2024-05-14 17:07:19 ET
More on Poseida Therapeutics
- Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
- Poseida gains on cell therapy pact with Astellas
- Poseida spikes after FDA orphan status for CAR-T therapy
- Seeking Alpha’s Quant Rating on Poseida Therapeutics
- Historical earnings data for Poseida Therapeutics